The American Lung Association announced a $25 million initiative to support the fight against COVID-19, as well as future viral pandemics.

Lions Health is a dedicated two-day event held annually within Cannes Lions in France. Lions Health is billed as the only place in the world to experience talks from leading pharmaceutical, healthcare, wellness, biotechnology and medical marketing practitioners. Event management says Lions Health is built to deliver the insights, ideas, tools and techniques that lead to life-changing outcomes.

Continuing its efforts to address high prescription drug costs, insurer Highmark entered into a new outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.

GlaxoSmithKline plc and Innoviva Inc. announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease. This is the first regulatory filing to be made in Japan for a triple COPD therapy in a single inhaler.